Skip to main content
رجوع
REGN logo

Regeneron Pharmaceuticals, Inc.

جودة البيانات: 100%
REGN
NASDAQ Healthcare Biotechnology
KWD 741.69
▲ KWD 5.16 (0.70%)
القيمة السوقية: 77.06B
نطاق اليوم
KWD 727.97 KWD 743.17
نطاق 52 أسبوعًا
KWD 476.49 KWD 821.11
حجم التداول
507,714
متوسط 50 يوم / 200 يوم
KWD 766.57 / KWD 651.78
الإغلاق السابق
KWD 736.53

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 17.1 0.3
P/B 2.5 2.9
ROE % 14.9 3.7
Net Margin % 31.4 3.8
Rev Growth 5Y % -2.8 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 862.740 +16.3%
Low: KWD 700.000 High: KWD 1,057.000
مكرر الربحية المستقبلي
16.2
ربحية السهم المستقبلية
KWD 45.381
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
16 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 71.972
KWD 64.896 – KWD 79.897
21 B 2
FY2029 KWD 67.381
KWD 60.757 – KWD 74.801
20 B 4
FY2028 KWD 60.830
KWD 48.910 – KWD 72.259
19 B 6

النقاط الرئيسية

Revenue declined -2.81% annually over 5 years
ROE of 14.87% — decent returns on equity
Net margin of 31.41% shows strong profitability
Debt/Equity of 0.09 — conservative balance sheet
Generating 4.08B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.80%

النمو

Revenue Growth (5Y)
-2.81%
Revenue (1Y)0.99%
Earnings (1Y)2.09%
FCF Growth (3Y)5.48%

الجودة

Return on Equity
14.87%
ROIC7.90%
Net Margin31.41%
Op. Margin24.95%

الأمان

Debt / Equity
0.09
Current Ratio4.13
Interest Coverage81.69

التقييم

P/E Ratio
17.11
P/B Ratio2.47
EV/EBITDA21.42
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.99% Revenue Growth (3Y) 4.57%
Earnings Growth (1Y) 2.09% Earnings Growth (3Y) 6.74%
Revenue Growth (5Y) -2.81% Earnings Growth (5Y) -13.58%
Profitability
Revenue (TTM) 14.34B Net Income (TTM) 4.50B
ROE 14.87% ROA 11.11%
Gross Margin 85.35% Operating Margin 24.95%
Net Margin 31.41% Free Cash Flow (TTM) 4.08B
ROIC 7.90% FCF Growth (3Y) 5.48%
Safety
Debt / Equity 0.09 Current Ratio 4.13
Interest Coverage 81.69 Dividend Yield 0.00%
Valuation
P/E Ratio 17.11 P/B Ratio 2.47
P/S Ratio 5.37 PEG Ratio 3.38
EV/EBITDA 21.42 Dividend Yield 0.00%
Market Cap 77.06B Enterprise Value 76.65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.34B 14.20B 13.12B 12.17B 16.07B
Net Income 4.50B 4.41B 3.95B 4.34B 8.08B
EPS (Diluted) 41.48 38.34 34.77 38.22 71.97
Gross Profit 12.24B 12.23B 10.87B 10.47B 13.35B
Operating Income 3.58B 3.99B 4.35B 5.39B 8.95B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 40.56B 37.76B 33.08B 29.21B 25.43B
Total Liabilities 9.30B 8.41B 7.11B 6.55B 6.67B
Shareholders' Equity 31.26B 29.35B 25.97B 22.66B 18.77B
Total Debt 2.71B 2.70B 2.70B 2.70B 2.70B
Cash & Equivalents 3.12B 2.49B 2.73B 3.11B 2.89B
Current Assets 18.02B 18.66B 19.48B 15.88B 14.01B
Current Liabilities 4.37B 3.94B 3.42B 3.14B 3.93B